Strategies to Accelerate the Development of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency of cytotoxic drugs.  This type of targeted delivery can minimize harm to healthy tissues, reducing side effects and potentially improving the therapeutic window. However, the complex structure of ADCs poses significant development and safety challenges for project teams.

In our latest White Paper, we share essential strategies for accelerating the development of ADCs, with special consideration given to ADC design, resistance mechanisms, safety assessment, and PK/PD studies.

ADC White Paper_WuXi AppTec

Download